DeFazio capsules oxaliplatin neoadjuvant chemotherapy on matrix metalloproteinase-9 and vascular endothe-lial growth factor in patients with advanced gastric cancer / 中国基层医药

ABSTRACT

Objective To study DeFazio capsules oxaliplatin neoadjuvant chemotherapy on matrix metallo-proteinase-9 ( MMP-9 ) and vascular endothelial growth factor ( VEGF ) in patients with advanced gastric cancer . Methods 92 patients with advanced gastric cancer were randomly divided into the two groups ,the observation group ( n=46 ) and the control group ( n=46 ) .Both two groups were used neoadjuvant chemotherapy , DeFazio capsules oxaliplatin chemotherapy for the observation group and capecitabine oxaliplatin chemotherapy for the control group . Expression of MMP-9 and VEGF was determined by immunohistochemistry in gastric cancer tissues .Results After chemotherapy,the total effective rate was 60.9%in the control group and 80.4%in the observation group.The total effective rate of the observation group was significantly higher (χ2 =6.42,P0.05).Neutropenia,neurotoxicity in the observation group were less than the control group (χ2 =5.68,4.18,all P0.05).After the chemothera-py,the positive expression rates of VEGF and MMP-9 in the control group were 45.7%,41.3%,respectively.Those of the observation group were 23.9%and 21.7%,respectively.VEGF and MMP-9 positive expression rates were sig-nificantly lower than before chemotherapy (χ2 =4.72,4.08,10.14,9.84,P<0.05,P<0.01).The observation group was significantly lower than the control group (χ2 =5.14,4.72,all P<0.05).Conclusion DeFazio capsules oxali-platin neoadjuvant chemotherapy can decrease MMP-9 and VEGF expression in patients with advanced gastric cancer .